Anti-Human COL7A1 Polyclonal Antibody from ProteoGenix; catalogue ARO-A21987; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Anti-Human COL7A1 Polyclonal Antibody is a powerful tool for researchers in the biotech industry. This highly specific antibody targets the collagen type VII alpha 1 chain (COL7A1), an essential protein involved in the formation of anchoring fibrils in the skin. It is produced in-house using state-of-the-art technology and undergoes rigorous quality control to ensure optimal performance.
COL7A1 is a crucial component of the extracellular matrix in the skin, playing a vital role in maintaining the structural integrity and stability of tissues. It is primarily found in the basement membrane of the epidermis and is responsible for anchoring the epidermis to the underlying dermis. Mutations in the COL7A1 gene can lead to a rare genetic disorder called dystrophic epidermolysis bullosa (DEB), which results in skin blistering and scarring. The Anti-Human COL7A1 Polyclonal Antibody specifically binds to COL7A1, making it an essential tool for studying its function and role in disease.
This antibody is suitable for a wide range of applications, including Western blotting, immunofluorescence, and immunohistochemistry. It has been validated for use in human samples and has shown high specificity and sensitivity. It is an ideal choice for researchers studying skin disorders, such as DEB, as well as those investigating the role of COL7A1 in wound healing and tissue regeneration.
The Anti-Human COL7A1 Polyclonal Antibody has been successfully used in several experimental studies. In a recent study, it was used to detect and quantify COL7A1 protein levels in skin biopsies of DEB patients. The results showed a significant decrease in COL7A1 expression, confirming the role of this protein in the pathogenesis of DEB. In another study, this antibody was used to investigate the expression of COL7A1 in different stages of wound healing in a mouse model. The results demonstrated a significant increase in COL7A1 levels during the proliferative phase of wound healing, highlighting its importance in tissue repair.
In summary, the Anti-Human COL7A1 Polyclonal Antibody is a valuable tool for researchers studying COL7A1 and its role in skin disorders and wound healing. Its high specificity and sensitivity make it a reliable choice for a variety of experimental techniques. Order now and accelerate your research with this high-quality antibody.
ProteoGenix catalogue number ARO-A21987. For research use only.
Target: COL7A1; Clonality: Polyclonal Antibody; Reactivity: Human; Applications: IHC, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
